Compare
Mosaic ImmunoEngineering Inc. vs Agentix Corp. vs Liminatus Pharma, Inc. vs Adaptin Bio, Inc.
| Latest fiscal year | Mosaic ImmunoEngineering Inc. CPMV | Agentix Corp. AGTX | Liminatus Pharma, Inc. LIMN | Adaptin Bio, Inc. APTN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$687.8K | -$485.6K | -$10.21M | -$5.17M |
| EPS (Diluted) | -$0.10 | -$0.01 | -$0.43 | -$0.66 |
| Operating cash flow | -$111.4K | -$108.5K | -$9.96M | -$4.78M |
| Free cash flow | n/a | n/a | -$9.98M | n/a |
| Cash & equivalents | $3.6K | $771 | n/a | $459.2K |
| Total assets | $19.9K | $771 | $512.8K | $619.2K |
| Total liabilities | $7.50M | $3.60M | $10.33M | $2.11M |
| Shareholders' equity | -$7.48M | -$3.60M | -$9.81M | -$1.49M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 7.24M | 40.07M | 27.06M | 8.66M |
Revenue, most recent five fiscal years
| Fiscal year | Mosaic ImmunoEngineering Inc. | Agentix Corp. | Liminatus Pharma, Inc. | Adaptin Bio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2023-03-31 | n/a | n/a |
| 1 year earlier | n/a | $1.2K Ended 2022-03-31 | n/a | n/a |
| 2 years earlier | n/a | n/a | n/a | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |